GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (HKSE:06669) » Definitions » EV-to-EBIT

Acotec Scientific Holdings (HKSE:06669) EV-to-EBIT : 52.72 (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Acotec Scientific Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Acotec Scientific Holdings's Enterprise Value is HK$1,400.3 Mil. Acotec Scientific Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$26.6 Mil. Therefore, Acotec Scientific Holdings's EV-to-EBIT for today is 52.72.

The historical rank and industry rank for Acotec Scientific Holdings's EV-to-EBIT or its related term are showing as below:

HKSE:06669' s EV-to-EBIT Range Over the Past 10 Years
Min: -155.85   Med: 28.95   Max: 95.17
Current: 53.43

During the past 5 years, the highest EV-to-EBIT of Acotec Scientific Holdings was 95.17. The lowest was -155.85. And the median was 28.95.

HKSE:06669's EV-to-EBIT is ranked worse than
84.72% of 458 companies
in the Medical Devices & Instruments industry
Industry Median: 20.17 vs HKSE:06669: 53.43

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Acotec Scientific Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was HK$2,829.3 Mil. Acotec Scientific Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$26.6 Mil. Acotec Scientific Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 0.94%.


Acotec Scientific Holdings EV-to-EBIT Historical Data

The historical data trend for Acotec Scientific Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acotec Scientific Holdings EV-to-EBIT Chart

Acotec Scientific Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -28.87 54.13 106.52

Acotec Scientific Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only -28.87 - 54.13 - 106.52

Competitive Comparison of Acotec Scientific Holdings's EV-to-EBIT

For the Medical Devices subindustry, Acotec Scientific Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acotec Scientific Holdings's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acotec Scientific Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Acotec Scientific Holdings's EV-to-EBIT falls into.



Acotec Scientific Holdings EV-to-EBIT Calculation

Acotec Scientific Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1400.254/26.562
=52.72

Acotec Scientific Holdings's current Enterprise Value is HK$1,400.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Acotec Scientific Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$26.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acotec Scientific Holdings  (HKSE:06669) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Acotec Scientific Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=26.562/2829.30992
=0.94 %

Acotec Scientific Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was HK$2,829.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Acotec Scientific Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$26.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acotec Scientific Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Acotec Scientific Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Acotec Scientific Holdings (HKSE:06669) Business Description

Traded in Other Exchanges
Address
16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN
Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.
Executives
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Nexus Partners Group Limited 2201 Interest of corporation controlled by you
Cosmic Elite Holdings Limited 2101 Beneficial owner
Li Jing 2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p. 2201 Interest of corporation controlled by you
Cpe Funds Iii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment Iii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment Ii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment (cayman) Limited 2101 Beneficial owner
Cpe Holdings Limited 2201 Interest of corporation controlled by you
Cpe Holdings International Limited 2201 Interest of corporation controlled by you
Cpe Gof Gp Limited 2201 Interest of corporation controlled by you
Cpe Global Opportunities Fund, L.p. 2201 Interest of corporation controlled by you
Boston Scientific Corporation 2201 Interest of corporation controlled by you
Cpechina Fund Iii, L. P.

Acotec Scientific Holdings (HKSE:06669) Headlines

No Headlines